SDC2 and diabetic cardiomyopathy: Given the early-onset model of experimental diabetic cardiomyopathy without cardiac fibrosis, we hypothesize that the CD362−- and CD362+-mediated immunomodulatory and anti-fibrotic effects may be reflected in a reduction in cardiac fibrosis at a later stage.